X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (128) 128
Newspaper Article (62) 62
Patent (16) 16
Dissertation (15) 15
Publication (13) 13
Book / eBook (5) 5
Book Review (5) 5
Book Chapter (3) 3
Web Resource (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (43) 43
pharmacology & pharmacy (36) 36
female (35) 35
male (35) 35
index medicus (33) 33
adult (26) 26
middle aged (26) 26
pharmacokinetics (25) 25
human necessities (16) 16
hygiene (16) 16
medical or veterinary science (16) 16
preparations for medical, dental, or toilet purposes (16) 16
aged (14) 14
analysis (12) 12
melanoma (12) 12
specific therapeutic activity of chemical compounds ormedicinal preparations (12) 12
half-life (11) 11
pharmacology/toxicology (11) 11
oncology (10) 10
dose-response relationship, drug (9) 9
pharmacodynamics (9) 9
proto-oncogene proteins b-raf - genetics (9) 9
young adult (9) 9
adolescent (8) 8
aged, 80 and over (8) 8
dosage and administration (8) 8
drug therapy (8) 8
medicine & public health (8) 8
melanoma - drug therapy (8) 8
melanoma - genetics (8) 8
pharmacology (8) 8
proto-oncogene proteins b-raf - antagonists & inhibitors (8) 8
research (8) 8
administration, oral (7) 7
cancer research (7) 7
drug interactions (7) 7
imidazoles - administration & dosage (7) 7
mutation (7) 7
oximes - administration & dosage (7) 7
tumors (7) 7
animals (6) 6
area under curve (6) 6
bioavailability (6) 6
cancer (6) 6
clinical trials (6) 6
computer simulation (6) 6
cross-over studies (6) 6
drug administration schedule (6) 6
efficacy (6) 6
french canadian literature (6) 6
infant (6) 6
models, biological (6) 6
population (6) 6
protein kinase inhibitors - pharmacokinetics (6) 6
1900-1999 (5) 5
antineoplastic agents - administration & dosage (5) 5
biomedicine (5) 5
care and treatment (5) 5
child, preschool (5) 5
dabrafenib (5) 5
double-blind method (5) 5
drug interaction (5) 5
metabolism (5) 5
model (5) 5
nonmem (5) 5
open-label (5) 5
protein kinase inhibitors - administration & dosage (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
antineoplastic agents - blood (4) 4
antineoplastic agents - pharmacokinetics (4) 4
biochemistry, general (4) 4
biological availability (4) 4
biomedical engineering (4) 4
disease-free survival (4) 4
health aspects (4) 4
imidazoles - adverse effects (4) 4
imidazoles - pharmacokinetics (4) 4
inhibitor (4) 4
map kinase kinase 1 - antagonists & inhibitors (4) 4
map kinase kinase 2 - antagonists & inhibitors (4) 4
medicine, general & internal (4) 4
mutations (4) 4
neoplasms - metabolism (4) 4
novel (4) 4
oximes - adverse effects (4) 4
oximes - pharmacokinetics (4) 4
pharmacy (4) 4
poliquin, daniel (4) 4
pyrazoles - pharmacokinetics (4) 4
pyridones - adverse effects (4) 4
pyridones - pharmacokinetics (4) 4
pyridones - therapeutic use (4) 4
pyrimidinones - adverse effects (4) 4
pyrimidinones - pharmacokinetics (4) 4
pyrimidinones - therapeutic use (4) 4
safety (4) 4
solid tumors (4) 4
acetates - pharmacokinetics (3) 3
analgesia (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 482 - 489
Journal Article
Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2019
ABSTRACTErdafitinib, a potent oral fibroblast growth factor receptor inhibitor, is a low extraction ratio drug highly bound to alpha-1-acid glycoprotein (AGP)... 
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 03/2010, Volume 9, Issue 2, pp. 289 - 300
Importance of the field: Measurement of the tradeoff between efficacy and safety is rarely done in a quantitative fashion. The use of a clinical utility index... 
multi-attribute decision | therapeutic index | benefit-risk | decision analysis | utility function | exposure-response
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2019, Volume 84, Issue 4, pp. 707 - 717
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2018, Volume 81, Issue 2, pp. 423 - 423
The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below... 
Oncology | Cancer Research | Medicine & Public Health | Pharmacology/Toxicology | Electrocardiography | Cardiac arrhythmia
Journal Article
Journal Article